Morusin Reverses Epithelial-Mesenchymal Transition in Gallbladder Cancer Cells by Regulating STAT3/HIF-1α Signaling.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gallbladder cancer is a lethal biliary tract malignancy with poor survival rates.
• Developing novel anti-cancer drugs is crucial for improving patient prognosis.
• Morusin, a flavonoid, is explored for its potential anti-neoplastic effects.

Purpose of the Study:

• To investigate the anti-cancer effects of morusin on gallbladder cancer.
• To determine morusin's impact on cancer cell proliferation, migration, and invasion.
• To elucidate the molecular mechanisms underlying morusin's action, focusing on EMT and related signaling pathways.

Main Methods:

• In vitro studies using gallbladder cancer cell lines.
• In vivo experiments to assess anti-tumor effects.
• Cell viability, colony formation, wound healing, and transwell assays.
• Analysis of epithelial-mesenchymal transition (EMT) markers.
• Western blot analysis to evaluate phospho-STAT3 and HIF-1α expression.

Main Results:

• Morusin significantly inhibited gallbladder cancer cell proliferation, migration, and invasion in vitro.
• Morusin treatment downregulated the expression of phospho-STAT3 and HIF-1α in gallbladder cancer cells, both in vitro and in vivo.
• Morusin effectively reversed EMT induced by phospho-STAT3 or HIF-1α.

Conclusions:

• Morusin exhibits significant anti-cancer properties against gallbladder cancer.
• Morusin exerts its effects by modulating the STAT3/HIF-1α signaling pathway.
• Morusin demonstrates potential as a therapeutic agent for gallbladder cancer by reversing EMT.